INT130748

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 0.71
Pain Relevance 1.02

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (ABCB1) ATPase activity (ABCB1) plasma membrane (ABCB1)
transmembrane transport (ABCB1)
Anatomy Link Frequency
liver 3
intestines 1
ABCB1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 5 98.86 Very High Very High Very High
vincristine 2 98.68 Very High Very High Very High
methotrexate 4 98.16 Very High Very High Very High
methadone 8 97.24 Very High Very High Very High
Bile 2 70.20 Quite High
ischemia 2 65.76 Quite High
Opioid 1 43.68 Quite Low
cINOD 2 24.08 Low Low
aspirin 2 20.72 Low Low
Morphine 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Injury 184 92.92 High High
Cv Unclassified Under Development 2 65.76 Quite High
Heart Rate Under Development 2 28.48 Quite Low
Critical Illness 14 22.68 Low Low
INFLAMMATION 6 22.64 Low Low
Hypoxia 4 20.52 Low Low
Chronic Renal Failure 16 5.00 Very Low Very Low Very Low
Renal Disease 12 5.00 Very Low Very Low Very Low
Uremia 8 5.00 Very Low Very Low Very Low
Disease 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast to its pharmacokinetics humans, methadone has a short elimination half-life, rapid clearance, and low oral bioavailability in dogs and the extent of absorption is not affected by inhibition of CYP3A, p-gp, and gastric acid secretion.
Negative_regulation (inhibition) of Localization (secretion) of p-gp associated with methadone and bioavailability
1) Confidence 0.42 Published 2005 Journal J. Vet. Pharmacol. Ther. Section Abstract Doc Link 16207309 Disease Relevance 0 Pain Relevance 0.68
Considering the role played by P-gp, the implications of reduced P-gp function in the intestines, liver, and kidneys are decreased gastrointestinal secretion, hepatic biliary excretion, and renal tubular secretion of P-gp substrates such as vinblastine, vincristine, methotrexate, digoxin, and grepafloxacin [32,33].


Negative_regulation (decreased) of Localization (secretion) of P-gp in liver associated with vincristine and methotrexate
2) Confidence 0.01 Published 2008 Journal Crit Care Section Body Doc Link PMC2646335 Disease Relevance 0.36 Pain Relevance 0.17
Considering the role played by P-gp, the implications of reduced P-gp function in the intestines, liver, and kidneys are decreased gastrointestinal secretion, hepatic biliary excretion, and renal tubular secretion of P-gp substrates such as vinblastine, vincristine, methotrexate, digoxin, and grepafloxacin [32,33].


Negative_regulation (decreased) of in intestines Localization (secretion) of P-gp in liver associated with vincristine and methotrexate
3) Confidence 0.00 Published 2008 Journal Crit Care Section Body Doc Link PMC2646335 Disease Relevance 0.36 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox